Sanofi Pasteur Vaccine Manufacturing Violations Cited In FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Sterility issues at the firm's Swiftwater, Pa. manufacturing facility should not impact supplies of the Fluzone influenza vaccine, FDA says.
You may also be interested in...
Sanofi GMP Problems Require Top-level Sit-down With FDA, But Product Impact Limited So Far
Agency’s warning letter also includes an uncommon request for a “global assessment” of operations. FDA says sterility of TheraCys lots manufactured since 2000 cannot be assured; company has halted manufacture of the bladder cancer drug and set limits on orders of its Pentacel vaccine.
HHS Boosts Pandemic Flu Vaccine Stockpile With Contracts Totaling $200 Mil.
Sanofi Pasteur, Novartis and GlaxoSmithKline stand to benefit from government's goal of adding 5.3 mil. doses to national stockpile.
HHS Boosts Pandemic Flu Vaccine Stockpile With Contracts Totaling $200 Mil.
Sanofi Pasteur, Novartis and GlaxoSmithKline stand to benefit from government's goal of adding 5.3 mil. doses to national stockpile.